


WHAT IS CLAIMED IS:

1. A compound of Formula I



wherein

- 10 R¹ is selected from

- 1) hydrogen,
- 2) halogen,
- 3) substituted or unsubstituted C₁-C₁₀ alkyl,
- 4) substituted or unsubstituted C₂-C₁₀ alkenyl,
- 5) substituted or unsubstituted C₂-C₁₀ alkynyl,
- 6) substituted or unsubstituted aryl,
- 7) substituted or unsubstituted C₃-C₁₀ cycloalkyl,
- 8) substituted or unsubstituted heterocyclyl,
- 9) -(CR^a₂)_nOR⁴, and
- 10) -(CR^a₂)_tC(O)OR⁴;

said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more of R⁷;

- R² is selected from

- 1) hydrogen,
- 2) substituted or unsubstituted aralkyl,
- 3) substituted or unsubstituted C₁-C₁₀ alkyl,
- 4) substituted or unsubstituted heterocyclyl,
- 5) substituted or unsubstituted aryl, and
- 6) substituted or unsubstituted C₃-C₁₀ cycloalkyl;

R³ is selected from

- 1) hydrogen,
- 2) halogen,
- 3) -C(O)R⁴,
- 5 4) substituted or unsubstituted C₁-C₁₀ alkyl,
- 5) substituted or unsubstituted aryl,
- 6) substituted or unsubstituted heterocyclyl,
- 7) substituted or unsubstituted C₃-C₁₀ cycloalkyl,
- 8) substituted or unsubstituted C₂-C₁₀ alkenyl, and
- 10 9) substituted or unsubstituted C₂-C₁₀ alkynyl;

R⁴ is independently selected from

- 1) hydrogen,
- 2) substituted or unsubstituted C₁-C₁₀ alkyl,
- 15 3) substituted or unsubstituted aryl,
- 4) substituted or unsubstituted heterocyclyl,
- 5) substituted or unsubstituted C₃-C₁₀ cycloalkyl,
- 6) substituted or unsubstituted C₂-C₁₀ alkenyl, and
- 7) substituted or unsubstituted C₂-C₁₀ alkynyl;

20

R⁶ is independently selected from

- 1) substituted or unsubstituted aryl,
- 2) substituted or unsubstituted heterocyclyl,
- 3) substituted or unsubstituted cycloalkyl, and
- 25 4) halogen;

R⁷ is independently selected from

- 1) hydrogen,
- 2) halogen,
- 30 3) substituted or unsubstituted C₁-C₁₀ alkyl,
- 4) substituted or unsubstituted C₂-C₁₀ alkenyl,
- 5) substituted or unsubstituted C₂-C₁₀ alkynyl,
- 6) substituted or unsubstituted C₃-C₁₀ cycloalkyl,
- 7) substituted or unsubstituted aryl,

- 8) substituted or unsubstituted heterocyclyl,
 9) $-\text{NO}_2$,
 10) $-\text{NR}_4(\text{CR}^{\text{a}_2})_n\text{C}(\text{O})\text{R}^4$,
 11) $-(\text{CR}^{\text{a}_2})_n\text{NR}^4_2$,
 5 12) $-(\text{CR}^{\text{a}_2})_n\text{NR}^4(\text{CR}^{\text{a}_2})_n\text{R}^6$,
 13) $-\text{CN}$,
 14) $-(\text{CR}^{\text{a}_2})_n\text{C}(\text{O})\text{R}^4$,
 15) $-(\text{CR}^{\text{a}_2})_n\text{C}(\text{O})(\text{CR}^{\text{a}_2})_n\text{OR}^4$,
 16) $-(\text{CR}^{\text{a}_2})_n\text{OR}^4$,
 10 17) $-(\text{CR}^{\text{a}_2})_n\text{R}^6$,
 18) $-(\text{CR}^{\text{a}_2})_n\text{C}(\text{O})\text{OR}^4$, and
 19) $-(\text{CR}^{\text{a}_2})_n\text{Si}(\text{R}^4)_3$;

R^{a} is independently selected from

- 15 1) hydrogen,
 2) substituted or unsubstituted C_1 - C_{10} alkyl,
 3) substituted or unsubstituted C_2 - C_{10} alkenyl,
 4) substituted or unsubstitute C_2 - C_{10} alkynyl,
 5) $-\text{OR}^4$,
 20 6) $-\text{C}(\text{O})\text{OR}^4$,
 7) $-\text{NR}^4_2$,
 8) substituted or unsubstituted aryl,
 9) substituted or unsubstituted heterocyclyl, and
 10) substituted or unsubstituted C_3 - C_{10} cycloalkyl;

25

n is independently 0 to 6;

t is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

30

2. The compound according to Claim 1,
 wherein

R^1 is selected from

- 35 1) hydrogen,

- 5
- 2) halogen,
 - 3) substituted or unsubstituted C₁-C₆ alkyl,
 - 4) substituted or unsubstituted C₂-C₁₀ alkynyl,
 - 5) substituted or unsubstituted aryl,
 - 6) substituted or unsubstituted C₃-C₁₀ cycloalkyl, and
 - 7) substituted or unsubstituted heterocyclyl;
- said alkyl, alkynyl, aryl, cycloalkyl, and heterocyclyl is optionally substituted with one or more of R⁷;

10 R² is selected from

- 1) substituted or unsubstituted aralkyl,
- 2) substituted or unsubstituted C₁-C₆ alkyl,
- 3) substituted or unsubstituted aryl, and
- 4) substituted or unsubstituted C₃-C₁₀ cycloalkyl;

15

R³ is selected from

- 1) halogen,
- 2) -C(O)R⁴, and
- 3) substituted or unsubstituted C₁-C₆ alkyl;

20

R⁴ is independently selected from

- 1) hydrogen,
- 2) substituted or unsubstituted C₁-C₆ alkyl,
- 3) substituted or unsubstituted aryl,
- 4) substituted or unsubstituted heterocyclyl, and
- 5) substituted or unsubstituted C₃-C₁₀ cycloalkyl;

25

or a pharmaceutically acceptable salt or stereoisomer thereof.

30

3. The compound according to Claim 2,
wherein

R¹ is selected from

- 1) substituted or unsubstituted C₁-C₆ alkyl,
- 2) substituted or unsubstituted C₂-C₁₀ alkynyl,

35

3) substituted or unsubstituted heterocyclyl and

4) substituted or unsubstituted aryl;

said alkyl, alkynyl, heterocyclyl and aryl is optionally substituted with one or more of R⁷;

5 R² is selected from

1) substituted or unsubstituted aralkyl, and

2) substituted or unsubstituted C₁-C₆ alkyl;


R³ is selected from

10 1) halogen, and

2) -C(O)R⁴;

or a pharmaceutically acceptable salt or stereoisomer thereof.

15 4. A compound of Formula II



wherein

20

R¹ is selected from

1) hydrogen,

2) halogen,

3) substituted or unsubstituted C₁-C₆ alkyl,

25

4) substituted or unsubstituted C₂-C₁₀ alkynyl,

5) substituted or unsubstituted aryl,

6) substituted or unsubstituted C₃-C₁₀ cycloalkyl, and

7) substituted or unsubstituted heterocyclyl;

said alkyl, alkynyl, aryl, cycloalkyl and heterocyclyl is optionally substituted with one or
30 more of R⁷;

R² is selected from

- 1) substituted or unsubstituted aralkyl, and
- 2) substituted or unsubstituted C₁-C₆ alkyl;

5 R⁴ is independently selected from

- 1) hydrogen,
- 2) substituted or unsubstituted C₁-C₁₀ alkyl,
- 3) substituted or unsubstituted aryl,
- 4) substituted or unsubstituted heterocyclyl,
- 10 5) substituted or unsubstituted C₃-C₁₀ cycloalkyl,
- 6) substituted or unsubstituted C₂-C₁₀ alkenyl, and
- 7) substituted or unsubstituted C₂-C₁₀ alkynyl;

R⁶ is independently selected from

- 15 1) substituted or unsubstituted aryl,
- 2) substituted or unsubstituted heterocyclyl,
- 3) substituted or unsubstituted C₃-C₁₀ cycloalkyl, and
- 4) halogen;

20 R⁷ is independently selected from

- 1) hydrogen,
- 2) halogen,
- 3) substituted or unsubstituted C₁-C₁₀ alkyl,
- 4) substituted or unsubstituted C₂-C₁₀ alkenyl,
- 25 5) substituted or unsubstituted C₂-C₁₀ alkynyl,
- 6) substituted or unsubstituted C₃-C₁₀ cycloalkyl,
- 7) substituted or unsubstituted aryl,
- 8) substituted or unsubstituted heterocyclyl,
- 9) -NO₂,
- 30 10) -NR⁴(CR^a₂)_nC(O)R⁴,
- 11) -(CR^a₂)_nNR⁴₂,
- 12) -(CR^a₂)_nNR⁴(CR^a₂)_nR⁶,
- 13) -CN,
- 14) -(CR^a₂)_nC(O)R⁴,

- 15) $-(\text{CR}^{\text{a}_2})_n\text{C}(\text{O})(\text{CR}^{\text{a}_2})_n\text{OR}^4$,
 16) $-(\text{CR}^{\text{a}_2})_n\text{OR}^4$,
 17) $-(\text{CR}^{\text{a}_2})_n\text{R}^6$,
 18) $-(\text{CR}^{\text{a}_2})_n\text{C}(\text{O})\text{OR}^4$, and
 19) $-(\text{CR}^{\text{a}_2})_n\text{Si}(\text{R}^4)_3$;

R^{a} is independently selected from

- 1) hydrogen,
- 2) substituted or unsubstituted C_1 - C_{10} alkyl,
- 3) substituted or unsubstituted C_1 - C_{10} alkenyl,
- 4) substituted or unsubstituted C_1 - C_{10} alkynyl,
- 5) $-\text{OR}^4$,
- 6) $-\text{C}(\text{O})\text{OR}^4$,
- 7) $-\text{NR}^4_2$,
- 8) substituted or unsubstituted aryl,
- 9) substituted or unsubstituted heterocyclyl, and
- 10) substituted or unsubstituted C_3 - C_{10} cycloalkyl;

n is independently 0 to 6;

t is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A compound selected from:

- benzyl 4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- benzyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2,5-diiodo-1H-pyrrole-3-carboxylate;
- methyl 5-(4-fluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-thien-2-yl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[3-(trimethylsilyl)prop-1-ynyl]-1H-pyrrole-3-carboxylate;

5

4'-benzyl 1-tert-butyl 3'-ethyl-5'-formyl-1H,1'H-2,2'-bipyrrole-1,4'-dicarboxylate;

benzyl 5-(3,5-dimethylisoxazol-4-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

10

benzyl 5-(1-benzofuran-2-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-nitrophenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(5-methyl-2-furyl)-1H-pyrrole-3-carboxylate;

15

benzyl 5-[3-(acetylamino)phenyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate;

20

benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate;

benzyl 5-(3-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-methoxyphenyl)-1H-pyrrole-3-carboxylate;

25

benzyl 4-ethyl-2-formyl-5-(5-formyl-2-furyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(phenylethynyl)-1H-pyrrole-3-carboxylate;

30

methyl 5-{3-[benzyl(methyl)amino]prop-1-ynyl}-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(2-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(4-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

35

- benzyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate;
- benzyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;
- 5 benzyl 4-ethyl-2-formyl-5-(4-methoxyphenyl)-1H-pyrrole-3-carboxylate;
- benzyl 4-ethyl-2-formyl-5-(2-methylphenyl)-1H-pyrrole-3-carboxylate;
- benzyl 4-ethyl-2-formyl-5-(3-methylphenyl)-1H-pyrrole-3-carboxylate;
- 10 benzyl 5-(2-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- benzyl 5-(3-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- 15 methyl 4-ethyl-2-formyl-5-[1-(3-hydroxypropyl)vinyl]-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-(5-hydroxypent-1-ynyl)-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate;
- 20 methyl 5-[3-(dimethylamino)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- methyl 5-(3,3-dimethylbut-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- 25 methyl 4-ethyl-2-formyl-5-(pyridin-2-ylethynyl)-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-(3-methoxyprop-1-ynyl)-1H-pyrrole-3-carboxylate;
- 30 methyl 5-[(2-bromophenyl)ethynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- methyl 5-[3-(1H-1,2,3-benzotriazol-1-yl)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- 35 methyl 4-ethyl-5-(2-ethylbutyl)-2-formyl-1H-pyrrole-3-carboxylate;

- methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;
- 5 methyl 5-(4-tert-butylphenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- methyl 5-(2,4-difluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- 10 methyl 4-ethyl-2-formyl-5-[3-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-[4-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclopentyl)ethynyl]-1H-pyrrole-3-carboxylate;
- 15 methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-methylbut-1-ynyl)-1H-pyrrole-3-carboxylate
- methyl 4-ethyl-2-formyl-5-(1-hexylvinyl)-1H-pyrrole-3-carboxylate;
- 20 methyl 4-ethyl-2-formyl-5-(1,3-thiazol-2-yl)-1H-pyrrole-3-carboxylate;
- methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- methyl 5-(5-chloropent-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
- 25 methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-phenylbut-1-ynyl)-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-(3-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;
- 30 methyl 4-ethyl-2-formyl-5-isopentyl-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-(3-methylthien-2-yl)-1H-pyrrole-3-carboxylate;
- methyl 4-ethyl-2-formyl-5-isobutyl-1H-pyrrole-3-carboxylate;
- 35

methyl 5-cyclohexyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

5 methyl 5-cyclopentyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(cyclohexylmethyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-sec-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

10

methyl 4-ethyl-2-formyl-5-(3-methoxy-2-methyl-3-oxopropyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate;

15 methyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate;


methyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;

20

or a pharmaceutically acceptable salt or stereoisomer thereof.


6. The compound according to Claim 5 that is selected from

25 methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate




benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate


30




methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate



methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate



10 methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate



or a pharmaceutically acceptable salt or stereoisomer thereof.

15

7. A trifluoroacetic acid salt of a compound of Claim 5 which is selected from

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate.

8. A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

9. A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

10. The method of Claim 9 wherein the protein kinase is an RTK.

11. The method of Claim 10, wherein the RTK is selected from IR, IGF-1R and IRR.

12. A method of treating a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

13. A method of Claim 12, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

- 1) cancer,
- 2) diabetes,
- 3) an autoimmune disorder,
- 4) a hyperproliferation disorder,
- 5) aging,
- 6) acromegaly, and

7) Crohn's disease.

14. A method of preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

15. A method of Claim 14, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

- 1) cancer,
- 2) diabetes,
- 3) an autoimmune disorder,
- 4) a hyperproliferation disorder,
- 5) aging,
- 6) acromegaly, and
- 7) Crohn's disease.

16. A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

20

17. A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

18. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) a retinoid receptor modulator,
- 4) a cytotoxic/cytostatic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,

- 5
- 9) a reverse transcriptase inhibitor,
 - 10) an angiogenesis inhibitor,
 - 11) a PPAR- γ agonist,
 - 12) a PPAR- δ agonists,
 - 13) an inhibitor of cell proliferation and survival signaling, and
 - 14) an agent that interferes with a cell cycle checkpoint.

10 19. The method of Claim 18, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

20. A method of preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

- 15
- 1) an estrogen receptor modulator,
 - 2) an androgen receptor modulator,
 - 3) a retinoid receptor modulator,
 - 4) a cytotoxic/cytostatic agent,
 - 5) an antiproliferative agent,
 - 6) a prenyl-protein transferase inhibitor,
 - 20 7) an HMG-CoA reductase inhibitor,
 - 8) an HIV protease inhibitor,
 - 9) a reverse transcriptase inhibitor,
 - 10) an angiogenesis inhibitor,
 - 11) a PPAR- γ agonist,
 - 25 12) a PPAR- δ agonists,
 - 13) an inhibitor of cell proliferation and survival signaling, and
 - 14) an agent that interferes with a cell cycle checkpoint.

30 21. The method of Claim 20, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

22. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

35

23. The method of Claim 22 wherein radiation therapy is also administered.

24. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

25. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

26. The method of Claim 26 wherein the GPIIb/IIIa antagonist is tirofiban.

27. A method of preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

28. The method of Claim 27 wherein the GPIIb/IIIa antagonist is tirofiban.

29. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.

30. A method of preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.